Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

News Conference News TCT 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

Yael L. Maxwell

October 29, 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

News Conference News TCT 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

Michael O'Riordan

October 27, 2024

EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER

News Conference News HFSA 2024

EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER

October 03, 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

News Conference News ACC 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Michael O'Riordan

April 06, 2024

No-Implant Shunt for HF Looks Safe, Feasible in Early Snapshot

News Conference News TVT 2023

No-Implant Shunt for HF Looks Safe, Feasible in Early Snapshot

Michael O'Riordan

June 12, 2023

Preliminary Results Suggest Benefit of Splanchnic Nerve Ablation in HFpEF

News Conference News THT 2023

Preliminary Results Suggest Benefit of Splanchnic Nerve Ablation in HFpEF

March 22, 2023

Earlier Interventions and Later Redos? ‘Mature’ TAVI Still Has Growing Pains

News Conference News PCR London Valves 2022

Earlier Interventions and Later Redos? ‘Mature’ TAVI Still Has Growing Pains

November 28, 2022

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

News Conference News TCT 2022

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

Yael L. Maxwell

September 19, 2022

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

March 02, 2022

News Conference News TCT 2021

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

Michael O'Riordan

November 10, 2021

Tricuspid Trio: TRISCEND, CLASP TR, and TriBAND Studies Show Advances

News Conference News EuroPCR 2021

Tricuspid Trio: TRISCEND, CLASP TR, and TriBAND Studies Show Advances

May 21, 2021

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

News Conference News HFSA 2020

Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study

October 12, 2020

In Long-term, Real-world Data CABG Bests PCI for Diabetic Patients With MVD

News Conference News ESC 2020

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Yael L. Maxwell

September 01, 2020

DynamX Bioadaptor Provides Promising Preliminary Results for De Novo Coronary Lesions

News Conference News EuroPCR 2020

DynamX Bioadaptor Provides Promising Preliminary Results for De Novo Coronary Lesions

June 30, 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

News Conference News EuroPCR 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Michael O'Riordan

June 26, 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

March 30, 2020

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

Clip-Based Tricuspid Repair Improves Regurgitation, Function, and Quality of Life: TRILUMINATE

News Conference News EuroPCR 2019

Clip-Based Tricuspid Repair Improves Regurgitation, Function, and Quality of Life: TRILUMINATE

Michael O'Riordan

May 22, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.